|
gptkbp:instance_of
|
gptkb:fragrance
|
|
gptkbp:activities
|
factor Xa inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Eliquis
|
|
gptkbp:clinical_trial
|
Phase III
thromboembolic disorders
|
|
gptkbp:contraindication
|
active bleeding
severe renal impairment
severe hepatic impairment
active peptic ulcer
hypersensitivity to apixaban
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:education
|
drug interactions
bleeding risk
dosage adherence
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
5 mg
2.5 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eliquis
|
|
gptkbp:indication
|
gptkb:deep_vein_thrombosis
gptkb:atrial_fibrillation
pulmonary embolism
|
|
gptkbp:interacts_with
|
antiplatelet agents
other anticoagulants
NSAI Ds
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_in
|
many countries
|
|
gptkbp:is_monitored_by
|
renal function
liver function
|
|
gptkbp:is_used_for
|
preventing blood clots
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketed_as
|
gptkb:2012
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:apixaban
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:provides_information_on
|
gptkb:European_Society_of_Cardiology
gptkb:healthcare_organization
gptkb:American_College_of_Cardiology
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
new indications
long-term safety
comparative effectiveness
|
|
gptkbp:side_effect
|
gptkb:fandom
nausea
bruising
rash
bleeding
liver enzyme elevation
hypotension
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
3
|